Clinical Daily Summary
Clinical Daily Summary: What Happened on October 4, 2026
Tozorakimab cut COPD flare-ups by up to 34% in two Phase 3 trials
The trials enrolled 2,306 people. Results varied by smoking status and blood eosinophil levels.
Today in brief
AstraZeneca said tozorakimab lowered COPD exacerbation rates by 30% in OBERON and 29% in TITANIA across current and former smokers, compared with placebo.1 Among former smokers, the reductions were 29% and 34%, respectively.1
Tozorakimab reduced COPD flare-ups in two trials
OBERON and TITANIA enrolled 2,306 people with symptomatic COPD and a recent history of repeated moderate or severe exacerbations.1 Participants received tozorakimab or placebo every four weeks for 52 weeks, alongside their regular inhaled maintenance treatment.1
Across current and former smokers, exacerbation rates were 30% lower with tozorakimab in OBERON and 29% lower in TITANIA than with placebo.1 Among former smokers, the rates were 29% lower in OBERON and 34% lower in TITANIA.1
A combined analysis found reductions of 43% among participants with blood eosinophil counts of at least 300 cells per microliter, compared with 23% among those with counts below 150.1 The analysis of patients with counts of at least 150 cells per microliter was conducted after the trials were designed.1
AstraZeneca says tozorakimab is intended to block interleukin-33 signaling and address inflammation and mucus dysfunction.1 Tozorakimab is also being tested for severe viral lower respiratory tract disease in a Phase 3 trial and for asthma in a Phase 2 trial.1 The FDA granted the drug Fast Track status for COPD and severe viral lower respiratory tract disease.1